Jan Van den Bossche
Angel Investor @ Fund+
Paris, France
Jan Van den Bossche is a Series B investor at Fund+ in Paris focused on Health Care and Biotechnology. Jan Van den Bossche is based out of Paris, Île-de-France, and is the Partner at Andera Partners and Board of Director at Alveus Therapeutics. Jan previously served as the Member Board Of Directors at Cardior Pharmaceuticals. Jan Van den Bossche attended KU Leuven.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jan Van den Bossche invests in
Stages Jan Van den Bossche invests in
Countries Jan Van den Bossche invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Diabetes 1 (25%)
- Life Science 1 (25%)
Stage
- Series B 2 (50%)
- Series A 1 (25%)
- Series C 1 (25%)
Country
- Belgium 1 (25%)
- Germany 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M / Series C / Oct 15, 2025 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $63.2M / Series B / May 03, 2022 | ||
| Indigo Diabetes nv (Indigo) is a young high-tech medical device company founded by Danaë Delbeke and her team ended in 2016. Indigo develops the world’s first invisible sensor for people living with diabetes to address their need for accurate glucose monitoring with improved user experience. Indigo exploits groundbreaking photonics technology thatrevolutionized the Internet during the last decades and now aims at transforming diabetes management. | $44.7M / Series B / Jul 27, 2020 |
Co-Investors
About Fund+
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.
Fund+ Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Desire Collen
Founder & Chairman
|
|||
Philippe Monteyne
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jan Van den Bossche invest in?
Jan Van den Bossche invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jan Van den Bossche?
Public channels for Jan Van den Bossche include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jan Van den Bossche last invest?
The most recent investment recorded for Jan Van den Bossche closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
